(en) To the Editor:We read the article by Maguire et al(1)withgreat interest. The authors present a single-arm phase 2 trialof elective nodal dose reduction for patients with locore-gionally advanced squamous cell carcinoma of the headand neck (HNSCC). Fifty-four patients were enrolled, witha median follow-up of 36 months. The dose to the electivenodal volume was lowered to 36 Gy.[...]
Nevens, D., Duprez, F., Daisne, J.-F., De Neve, W., & Nuyts, S. (2018). In Regard to Maguire et al. International Journal of Radiation: Oncology - Biology - Physics, 101(3), 746-747. https://doi.org/10.1016/j.ijrobp.2018.03.031 (Original work published 2018)